Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016

William Goodnight, MD, MSCR

Address for correspondence William Goodnight, MD, MSCR, Maternal Fetal Medicine, University of North Carolina at Chapel Hill School of Medicine, 3010 Old Clinic Building, CB # 7516, Chapel Hill, NC 27599-7516 (e-mail: william_goodnight@med.unc.edu).

Abstract

While the preterm neonate continues to benefit from improved perinatal care, the rate of preterm birth in the United States remains significant. An increasing body of scientific literature has demonstrated the benefits of maternal progesterone administration in reducing primary and recurrent preterm birth. Intramuscular hydroxyprogesterone caproate is indicated in singleton pregnancies in women with a prior spontaneous preterm birth, while vaginal progesterone demonstrates similar efficacy in prolonging pregnancy in women with asymptomatic cervical shortening in the midtrimester. Given these favorable benefits, the use of progesterone has been expanded to other clinical situations at risk for preterm birth with less rigorous scientific evidence. This review highlights the current evidence-based clinical applications of progesterone for prevention of preterm birth.

Keywords
- preterm birth
- recurrent preterm birth
- progesterone
- vaginal progesterone
- cervical shortening

Progesterone Formulations and Mechanisms of Action

Multiple formulations of progesterone are currently commercially available and have been used for the purposes of prevention of PTB (►Table 1). As of 2016, there is one FDA-approved progesterone, 17-hydroxyprogesterone caproate (17P) (Makena, AMAG Pharmaceuticals, Inc., Waltham, MA), approved for prevention of spontaneous PTB in singleton pregnancies in patients with a prior spontaneous PTB. 17P is approved for prevention of spontaneous PTB in singleton pregnancies in patients with a prior spontaneous PTB. Micronized progesterone (MP) is administered via the vaginal route as compounded micronized vaginal suppositories (First Progesterone, CutisPharma Wilmington, MA), a vaginal gel (Crimone 8%, Watson Pharma, Inc, Parsippany, NJ; Prochieve, Fleet Laboratories Ltd., Watford, United Kingdom), or vaginal administration of oral MP capsules (Prometrium, Solvay Pharmaceuticals, Inc, Marietta, GA). Oral progesterone formulations for PTB prevention have more limited data and inconsistent results.

In the United States, 11.4% of pregnancies are delivered prior to 37 weeks' gestational age, with 1.5% of singleton births occurring prior to 33 weeks' gestational age. Despite improvements in the perinatal care of the premature neonate, prematurity continues to be a leading factor in perinatal morbidity; thus, interventions to reduce the rate of spontaneous preterm birth (PTB) can have significant impacts on perinatal morbidity. Progesterone administration in certain high-risk pregnancies has demonstrated ability to significantly prolong pregnancy and reduce the risk of PTB. Given the success of progesterone in specific clinical trials, there has been a widening of the indications for use of progesterone for prevention of prematurity to other clinical circumstances. As progesterone administration does not appear to reduce the rate of PTB in a general, low-risk population, identification of those who will benefit from progesterone is important. The aim of this review is to describe the available formulations of and the current evidence-based applications for the clinical use of progesterone for the prevention of spontaneous PTB.
Table 1 Progesterone type, dosing, and clinical indications

<table>
<thead>
<tr>
<th>Progesterone</th>
<th>Dosing</th>
<th>How supplied</th>
<th>Clinical indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>17-hydroxyprogesterone caproate (Makena)</td>
<td>250 mg IM, weekly</td>
<td>250 mg/ml; 5 mL vial</td>
<td>Singleton pregnancy in woman with prior singleton spontaneous preterm birth between 16 and 36 weeks gestation*</td>
</tr>
<tr>
<td>Micronized progesterone (First Progesterone)</td>
<td>200 mg via vaginal route nightly</td>
<td>Vaginal suppositories; compounding kit; 30 each per box</td>
<td>Ultrasound identification of short cervix prior to 24 weeks’ gestational age</td>
</tr>
<tr>
<td>Micronized progesterone (Prometrium)</td>
<td>200 mg via vaginal route nightly</td>
<td>200 mg oral capsule</td>
<td>Ultrasound identification of short cervix prior to 24 weeks’ gestational age</td>
</tr>
<tr>
<td>Progesterone gel: (Crinone 8% gel)</td>
<td>1.125 g/90 mg via vaginal route nightly</td>
<td>1.125 g prefilled applicators</td>
<td>Ultrasound identification of short cervix prior to 24 weeks’ gestational age</td>
</tr>
<tr>
<td>Progesterone gel (Prochieve 8% gel)</td>
<td>1.4 gram/90 mg via vaginal route nightly</td>
<td>90 mg prefilled applicators</td>
<td>Ultrasound identification of short cervix prior to 24 weeks’ gestational age</td>
</tr>
</tbody>
</table>

*FDA Approved indication.

The mechanism of action of progesterone for prematurity prevention is poorly understood, but likely occurs through several pathways. Progesterone is a steroid hormone that affects target tissues, including the breast, ovaries, uterus, and central nervous system, via binding of progesterone receptors (PR-A and PR-B). Binding of progesterone to progesterone receptors results in a subsequent conformational change in the receptor leading to binding to target genes, ultimately affecting the regulation of gene transcription. The major purported end-organ effects of progesterone that influence PTB include an anti-inflammatory effect, which attenuates the proinflammatory state associated with initiation of labor, and a stabilization of progesterone effects on the myometrium resulting in maintenance of uterine quiescence.

While the clinical significance is unclear as it relates to prevention of PTB, plasma concentrations of progesterone are significantly greater with intramuscular administration, while vaginal administration results in greater uterine tissue concentrations. The optimal timing for initiation of progesterone therapy is not established.

Progesterone has been shown to have a favorable maternal and fetal safety profile based on an extensive history of first trimester applications in fertility support as well as secondary analyses of 17P clinical trials (when used in the context of prematurity prevention). No increase in fetal anomalies or early childhood developmental delays has been associated with maternal progesterone use, resulting in a Pregnancy Category B US FDA classification for 17P. In addition, 17P is not associated with other adverse maternal obstetrical complications such as gestational diabetes. The most common side effects from 17P include incision site pain (35%) and swelling (17%), pruritus (8%), and nausea (6%).

Prior Spontaneous Preterm Birth

The most well-studied indication for progesterone for PTB prevention is for the prevention of recurrent PTB. The Society for Maternal-Fetal Medicine and American College of Obstetricians proposed definitions of spontaneous PTB (Fig. 1). In the first large randomized clinical trial, Meis et al demonstrated that in women with a current singleton pregnancy with a prior pregnancy complicated by PTB between 20/7 and 36/6 weeks’ gestational age, administration of 17P starting at 16 to 20 weeks’ gestational age resulted in a 30 to 40% reduction in the risk of recurrent PTB (<37 weeks estimated gestational age) (relative risk [RR], 0.66; 95% confidence interval [CI], 0.54–0.81; rate of PTB, 36.3 vs. 54.9%; number needed to treat 5–6). In addition, 17P was associated with a reduction in perinatal morbidity including reductions in necrotizing enterocolitis, intraventricular hemorrhage, and need for supplemental oxygen. Subsequent trials have reinforced these findings. The optimal reduction in PTB appears with initiation of 17P prior to 21 weeks’ EGA, but some benefit is noted with initiation of 17P by 27 weeks’ EGA. Early cessation of 17P has been associated with an increased risk of preterm delivery compared with continuation to 36 weeks.

Vaginal progesterone for the prevention of recurrent PTB with unknown cervical length has been less well evaluated with inconsistent results and thus IM progesterone remains the first-line recommendation. Thus, in women with a current singleton pregnancy with a prior spontaneous PTB between 16/6 and 36/6 weeks, administration of 17P on vaginal route starting at 16 and 20/6 weeks and continued until 36/6 weeks, is recommended. Vaginal progesterone may be substituted if IM progesterone is not available.
Asymptomatic Cervical Shortening

Asymptomatic cervical shortening between 18 and 24 weeks of EGA is associated with an increased risk of PTB. A transvaginal ultrasound measured cervical length ≤ 25 mm in the midtrimester in singleton pregnancies is consistent with the 10th percentile for the population and is associated with a risk of PTB of 25 to 30%, with a cervical length < 20 mm (3rd percentile) associated with a 50% risk of PTB, with similar associations with PTB in multiple gestation. Several randomized trials and a patient-level meta-analysis have demonstrated a reduction in PTB in women with asymptomatic cervical shortening (defined as transvaginal cervical length ≤ 20 mm between 16 and 24 weeks EGA) with the use of vaginal progesterone. In a meta-analysis of five high-quality trials with 775 patients, Romero et al demonstrated that the use of vaginal progesterone in the presence of midtrimester ultrasound cervical length ≤ 25 mm was associated with a 31% reduction in risk of PTB < 35 weeks (RR, 0.69; 95% CI, 0.55–0.88) and similar reductions in PTB at < 33 weeks (RR, 0.58; 95% CI, 0.42–0.80) and < 28 weeks (RR, 0.50; 95% CI, 0.30–0.81). Significant reductions in respiratory distress syndrome, birthweight < 1,500 g, admission to neonatal intensive care unit, and composite neonatal morbidity and mortality were noted in those receiving vaginal progesterone. Population-based cervical length screening with the use of vaginal progesterone has been modeled as a cost-effective approach for the reduction of PTB in a general obstetric population, and is estimated to be superior to 17P use without screening or screening only women with a risk factor for PTB. The optimal timing and frequency of cervical length screening remains unproven, and universal cervical length screening has not been evaluated in large, randomized clinical trials, and thus individualization of institutional/regional screening protocols is suggested.

Clinical situations will arise where a patient with prior PTB currently undergoing treatment with 17P will develop cervical shortening. There are currently no randomized trials to address this specific circumstance. A meta-analysis by Berghella et al demonstrated a 30% (RR, 0.70; 95% CI, 0.55–0.89) reduction in PTB prior to 35 weeks of gestational age and a 36% reduction in composite neonatal morbidity and mortality with the addition of cervical cerclage in women with a prior PTB who develop cervical shortening in the midtrimester; thus, the addition of cerclage has been suggested in this setting. Importantly, the majority of women in this meta-analysis were not receiving 17P. A secondary analysis of a trial of cerclage for ultrasound
identified short cervix did not demonstrate benefit of addition of cerclage in women currently receiving 17P who developed midtrimester ultrasound cervical length < 25 mm. In contrast, Conde-Agudelo et al conducted a systematic review and indirect comparison meta-analysis to compare cerclage and vaginal progesterone for asymptomatic short cervix in women with prior PTB. In this analysis of patients not currently receiving 17P, cerclage was not superior to vaginal progesterone in the prevention of PTB in women with a prior PTB and cervical length prior to 24 weeks ≤ 25 mm, leading these authors to propose the use of vaginal progesterone over cerclage as a less invasive intervention. These authors also propose that in women with prior PTB currently receiving 17P who develop short cervix prior to 24 weeks’ EGA, consideration of conversion from IM to vaginal progesterone may be appropriate; however, there is a paucity of data to this approach. Finally, Alfirevic et al evaluated a retrospective cohort of women with a prior PTB and ultrasound short cervix. In this analysis, treatments with pessary, vaginal progesterone, or cerclage were associated with similar rates of PTB.

Thus, in women who are not currently taking 17P, daily vaginal progesterone from time of diagnosis until 360/7 weeks is recommended for the identification of a transvaginal ultrasound cervical length ≤ 20 mm between 16 and 240/7 weeks in an asymptomatic patient. Ultrasound screening protocols for cervical length between 16 and 240/7 weeks should be individualized on an institutional/regional basis. In women currently receiving 17P, progressive cervical shortening prior to 24 weeks’ EGA, defined as transvaginal cervical length ≤ 25 mm, may be treated with placement of cervical cerclage. Other management options in women with progressive cervical shortening with less rigorous study include addition or substitution of vaginal progesterone for IM progesterone or placement of vaginal pessary. Management of asymptomatic cervical shortening beyond 24 weeks is not well studied.

**Arrested Preterm Labor**

Several investigators have utilized 17P or vaginal progesterone for prevention of PTB following an episode of preterm labor. Rozenberg et al conducted an open-label randomized trial of 17P, 500 mg twice weekly IM, in women following an episode of preterm labor defined as cervical length ≤ 25 mm, contractions > 2 per 10-minute period, and cervix less than 3 cm dilated. 17P administration following acute tocolysis was not associated with a difference in time to delivery (61 vs. 63 days; p = 0.5) or in PTB rates at 37, 34, or 32 weeks’ EGA. A meta-analysis in 2015 of five randomized trials of 17P following an episode of symptomatic preterm labor demonstrated a 2.28 week (95% CI 1.56–13.51) later gestational age at delivery, 8.36 day (95% CI, 3.2–13.5) longer length of gestation, and higher mean birthweight (224.3 g; 95% CI, 70.81–377.74) in women who received 17P compared with controls. However, there was no difference in the rates of PTB < 37 or < 34 weeks with treatment of 17P following an episode of symptomatic preterm labor. A meta-analysis of vaginal progesterone following tocolysis for symptomatic preterm labor similarly demonstrated no difference in the rates of delivery < 37 and < 34 weeks’ EGA, latency from randomization to delivery, or difference in respiratory distress syndrome, but again did demonstrate an association with increased birthweight (mean difference 203.32 g; 95% CI, 110.85–295.80; p = 0.032).

Thus, based on the current scientific data, 17P and vaginal progesterone are currently not indicated for prevention of PTB following arrested asymptomatic preterm labor in singleton or twin pregnancies.

**Twin Pregnancy Prevention of Preterm Birth**

Given the high rate of spontaneous PTB in multiple gestations, effective measures to prevent PTB would be highly valuable. Randomized trials of 17P for the primary prevention of PTB in twin pregnancy with unknown cervical length have not demonstrated efficacy of 17P for the prevention of PTB or reduction in overall twin morbidity due to prematurity. Similarly, 17P has not demonstrated a reduction in PTB in twin pregnancies with ultrasound short cervix < 25 mm. Vaginal progesterone in unselected twin pregnancies has also not demonstrated a reduction in the risk of PTB. Vaginal progesterone for midtrimester short cervix in twin pregnancies has not demonstrated lower rates of PTB compared with controls. In a meta-analysis by Romero et al, vaginal progesterone for cervical shortening (<25mm in the mid-trimester) did not reduce the rate of PTB prior to 33 weeks of gestation (30.4 vs. 44.8%; RR, 0.70; 95% CI 0.34–1.44), but was associated with a reduction in the composite neonatal morbidity (23.9 vs. 39.7%; RR, 0.52; 95% CI, 0.29–0.93) and demonstrated a reduction in the risk of PTB in twins < 37 weeks in women with no prior PTB (RR, 0.52; 95% CI, 0.29–0.93).

Currently, based on the available scientific evidence, 17P and vaginal progesterone are not recommended for the primary prevention of PTB in unselected twin pregnancies, and 17P is not recommended for use in women with twin pregnancy with midtrimester cervical shortening. The influence of vaginal progesterone in prevention of PTB in the setting of a short cervical length in twin pregnancy (< 25 mm) remains unclear, with some data suggesting improved neonatal outcomes. Ongoing large randomized clinical trials may provide further guidance in this clinical circumstance.

**Conclusion**

Progesterone administration has been demonstrated to be a safe and effective intervention to date in the reduction of the risk of recurrent PTB as well as primary prevention of PTB in women with asymptomatic cervical shortening in the midtrimester. represents suggested guidelines for use of progesterone based on current scientific evidence and recommendations by Society for Maternal-Fetal Medicine and American College of Obstetricians and Gynecologists incorporating cervical length screening options. Identification of candidate patients and timely administration of progesterone will be expected to result in a reduction in the morbidity associated with PTB.
References

34. Reddy U. A trial of pessary and progesterone for preterm prevention in twin gestation with a short cervix (PROSPECT). Available at: ClinicalTrials.gov. Published 2015